Navigation Links
Antipsychotic Drug Controls Some Symptoms in Autism Disorder

Risperidone, a drug used to control schizophrenia symptoms, may also help treat behaviors found in autism spectrum disorder, according to a new review of studies.//

The reviewers looked at three randomized, placebo-controlled studies of risperidone (Risperdal) involving 211 participants, including 31 adults.

“[We found] that risperidone may be beneficial for various aspects of autism including irritability, repetition and hyperactivity,” said researchers led by Dr. Ora Jesner of the University of Bristol, in England. But the drug’s benefits may be offset by its side effects, with weight gain the most prominent.

Often diagnosed within the first three years of life, autism spectrum disorder leads to difficulties with social relationships, language and communication skills. Symptoms include withdrawal from social interactions, irritability, problems communicating and repetitive behaviors.

It is known as a “spectrum” disorder because there is a wide variation in how it affects individuals. Figures from the U.S. Centers for Disease Control and Prevention show that as many as 1.5 million Americans may have some form of the disorder.

“Autism spectrum disorder affects many families worldwide,” Jesner said. “At present many of the interventions available are not evidence-based.” He said he and co-author Dr. Mehrnoosh Aref-Adib “wanted to analyze the evidence for one important antipsychotic [drug] used for the condition.”

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Because of the small number of studies, wide range of different scales used to assess outcomes and sizes of the trials themselves, the research ers were only able to look at how well the patients responded for the three specific symptoms of irritability, repetitive movement and social withdrawal.

In addition to weight gain, significant side effects included involuntary muscle movements. As the studies were of short duration, long-term side effects and usefulness remain unknown. Since risperidone does not cure the disorder and may have to be continued for a long period of time, this is an important missing piece.

Susan Levy, M.D., director of the Regional Autism Center at The Children’s Hospital of Philadelphia, said that the authors’ weak support for the medication in the conclusion surprised her.

“The researchers seemed to be lukewarm towards their positive findings,” said Levy, who was not involved with the study. “From my personal experience, this medication can be quite helpful for behavioral difficulties.”

The Cochrane reviewers and Levy stress that parents and caregivers should be careful about expecting too much from the medication when talking about this treatment with their doctors. Not all behavioral problems can be helped with risperidone and both side effects and improvements from the drug should be considered.

“As ASD is diagnosed at a young age and these short trials lack long-term data, parents or caregivers need to be aware it is not known how long the medication needs to be continued — potentially for a lifetime,” the researchers said. “This is particularly important given the side effects.”

Levy termed risperidone “a more serious medication” that she would reserve for more serious difficulties.

“It needs to be stressed to the parents and others that this is not a cure for autism or for the core symptoms of ASD,” Levy said. “But it works well for some of the associated problems.” Source-Newswise
SRM
'"/>




Related medicine news :

1. Antipsychotic Drug Linked to Pulmonary Embolism
2. New Antipsychotic Medications have Little Advantage Over Older Drugs
3. Antipsychotics – not effective in treating Alzheimer
4. No Evidence to Support Many Off-label Uses of Atypical Antipsychotics
5. Scientists Uncover Cause of Antipsychotic Drug Weight Gain
6. Study Sheds Light on Value of Newer Antipsychotic Drugs for Schizophrenia
7. Scientists Discover Hormone That Controls Hunger
8. Brain behind the Brawn: Vital Molecule in the Brain Controls Appetite
9. Stronger Quadricep Controls Knee Osteoarthritis
10. Pair of MicroRNA Molecules Controls Major Oncogene in Most Common Leukemia
11. Molecular ‘On/Off Switch’ Controls Immune Defenses Against Viruss
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway ... call for a minimum wage raise to $12 an hour by 2020 and then adjusting ... restore the lost value of the minimum wage, assure the wage floor does not erode ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, ... Board will take whatever measures required to build a ... stock which is currently listed on the OTC Markets-pink ... Company Chairman and CEO, "We are seeing an anomaly ... to understand, not only by the Company, but shareholders ...
Breaking Medicine Technology: